8-K: Exagen Reports Record Q1 2026 Revenue, Improved Adjusted EBITDA

Exagen Inc. announced record first quarter 2026 revenue of $17.3 million, a 12% increase year-over-year, alongside an improved adjusted EBITDA loss of $2.2 million.

Summary

• Exagen Inc. reported financial results for the first quarter ended March 31, 2026.
• Total revenue reached a record $17.3 million, up 12% from $15.5 million in the first quarter of 2025.
• Gross margin was 59.0%, a slight increase from 58.9% in the prior year period.
• Operating expenses increased to $13.6 million from $12.5 million.
• The operating loss was $3.4 million, compared to $3.4 million in Q1 2025.
• Net loss for the quarter was $4.0 million, or $(0.17) per share, compared to a net loss of $3.8 million, or $(0.20) per share, in Q1 2025.
• Adjusted EBITDA loss improved by 14% to $2.2 million from $2.5 million in Q1 2025.
• Cash and cash equivalents stood at $21.5 million at the end of the quarter.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with record revenue, improved EBITDA loss, and cash reserves ahead of expectations, indicating solid operational execution and a favorable outlook for the year.

Positives

• Achieved record total revenue of $17.3 million, a 12% increase compared to the first quarter of 2025.
• AVISE CTD test volume grew by 10% compared to the first quarter of 2025.
• AVISE CTD trailing-twelve-month average selling price (ASP) increased to $444 per test, a 6% rise from $419 in the prior year.
• Adjusted EBITDA loss improved by 14% to $2.2 million compared to $2.5 million in the first quarter of 2025.
• Ended the quarter with approximately $22 million in cash and cash equivalents, ahead of expectations.

Negatives

• The company reported a net loss of $3.97 million for the quarter.
• Operating expenses increased to $13.6 million from $12.5 million in the prior year period.
• The company continues to operate at a loss, with an operating loss of $3.4 million.

Risks

• Delays in reimbursement and coverage decisions from Medicare and third-party payors.
• Interactions with regulatory authorities.
• Delays in ongoing and planned clinical trials involving its tests.
• Potential effects of inflation and tariffs on Exagen's margins.
• Changes in laws and regulations related to Exagen's regulatory requirements.
• The company's commercial success depends upon attaining and maintaining significant market acceptance of its testing products.
• Exagen's ability to obtain additional funding.
• Third-party payors not providing coverage and adequate reimbursement for Exagen's testing products, including Exagen's ability to collect on funds due.

Future Outlook

The Company continues to expect full-year 2026 revenue of $70 million to $73 million.

Management Comments

• First quarter results establish a solid start to 2026, reflecting our teams disciplined execution and effective revenue cycle management.
• Exagen is uniquely committed to providing clarity for autoimmune patients and confidence for clinicians.
• We have built a foundation to expand our reach and advance innovation in a market with significant unmet need.

Industry Context

StockSavvy.ai notes that Exagen's reported record revenue and improved adjusted EBITDA in Q1 2026 align with a trend of growth in specialized diagnostic testing, particularly in the autoimmune disease space, where accurate and early diagnosis is critical for patient outcomes and managing healthcare costs.

Comparison to Industry Standards

• Exagen's revenue growth of 12% in Q1 2026 outpaces the general diagnostic testing market growth, which can fluctuate but typically sees single-digit percentage increases year-over-year.
• The improvement in Adjusted EBITDA loss by 14% suggests better operational efficiency, a key focus for many companies in the healthcare diagnostics sector aiming to reach profitability.
• The increase in AVISE CTD ASP by 6% indicates successful pricing strategies or a shift towards higher-value tests, a common objective for companies seeking to improve per-unit economics.

Stakeholder Impact

• Shareholders: Potential for increased value due to revenue growth and improved financial performance.
• Clinicians: Continued provision of accurate and timely diagnostic tools for autoimmune diseases.
• Patients: Improved clarity and confidence in decision-making for chronic and debilitating autoimmune conditions.
• Payors: Continued engagement regarding reimbursement and coverage decisions for testing products.

Next Steps

• Continue to execute on disciplined operations and effective revenue cycle management.
• Expand reach and advance innovation in the autoimmune testing market.
• Focus on achieving full-year 2026 revenue guidance of $70 million to $73 million.

Key Dates

Recommendation

The company demonstrated positive momentum with record revenue and improved EBITDA, aligning with its full-year guidance. However, the continued net loss and the inherent risks in the healthcare reimbursement landscape warrant a 'hold' position until sustained profitability is achieved and key risks are mitigated.

Keywords

Exagen, AVISE CTD, Autoimmune Testing, Q1 2026 Results, Revenue Growth, Adjusted EBITDA, Healthcare Diagnostics, Nasdaq: XGN